Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA-assisted psychotherapy for chronic treatment-resistant PTSD in Australian war veterans
ACTRN12612000219886Phase 2Withdrawn
- Sponsor
- PRISM
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of midomafetamine in post-traumatic stress disorder (PTSD) (4 arms), sponsored by PRISM. Primary endpoint: Change in PTSD symptoms measured by Clinician-Administered PTSD Scale. Planned start Sep 2013; status: withdrawn.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on ACTRN12612000219886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000219886.